Compare Amgen, Inc. (AMGN) vs Walt Disney Co (DIS) Price & Performance

AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.

The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.

Disney (DIS) trades at $95.63, down 0.55% on the day, reflecting near-term bearish technical signals despite strong fundamentals. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $1.57 exceeding expectations of $1.49, and maintains solid profitability with a net income margin of 11.54%. Revenue growth continues, reaching $94.43 billion in 2025, while analyst consensus remains bullish with a $131.89 price target. Recent news highlights advertising opportunities with major events like the Super Bowl, though box office performance for new releases has faced challenges.

Disney presents a compelling long-term investment case driven by earnings momentum and strategic initiatives, but faces risks from content performance variability and regulatory scrutiny. The stock's current valuation multiples, including a P/E of 15.3, appear reasonable relative to growth prospects. Investors should weigh the strong analyst support against technical weakness and competitive pressures in streaming and parks.